NCT04646187View on ClinicalTrials.gov

De-escalation of Anti-TNF Therapy in Inflammatory Bowel Disease

PHASE4Enrolling by invitationINTERVENTIONAL
Enrollment

148

Participants

Timeline

Start Date

March 11, 2021

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions
Inflammatory Bowel DiseasesCrohn DiseaseColitis, Ulcerative
Interventions
BIOLOGICAL

Infliximab

Dosing interval lengthening from 8 to 12 weeks

BIOLOGICAL

Adalimumab

Dosing interval lengthening from 2 to 3 weeks

Trial Locations (7)

9000

Universitair Ziekenhuis Gent, Ghent

B-4000

Centre hospitalier universitaire de Liège, Liège

Unknown

Centre hospitalier régional de la Citadelle, Liège

6816 AD

Rijnstate Hospital, Arnhem

5623 EJ

Catharina Hospital Eindhoven, Eindhoven

9700 RB

University Medical Center Groningen, Groningen

08907

Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat

Sponsors

Collaborators (1)

Bühlmann Laboratories AG
All Listed Sponsors
collaborator

European Crohn´s and Colitis Organisation

UNKNOWN

collaborator

Bühlmann Laboratories AG

INDUSTRY

lead

University Medical Center Groningen

OTHER

NCT04646187 - De-escalation of Anti-TNF Therapy in Inflammatory Bowel Disease | Biotech Hunter | Biotech Hunter